Sign in to continue:

Saturday, March 7th, 2026

Averin Capital Acquisition Corp. Announces Partial Exercise of IPO Over-Allotment, Raising $33.86 Million 1





Averin Capital Acquisition Corp. Announces Partial Exercise of Over-Allotment Option

Averin Capital Acquisition Corp. Announces Closing of Partial Exercise of IPO Over-Allotment Option

New York, NY, March 5, 2026 – Averin Capital Acquisition Corp. (NASDAQ: ACAAU) has announced a significant development in its initial public offering (IPO): the underwriters have partially exercised their over-allotment option, purchasing an additional 3,386,008 units at the public offering price of \$10.00 per unit. This transaction has resulted in additional gross proceeds of approximately \$33,860,080 for the company.

Key Points for Investors

  • Partial Exercise of Over-Allotment Option: The underwriters have exercised their right to purchase more shares, albeit not the entire over-allotment option. There remains an option to purchase up to 363,992 additional units, which could bring in further capital if exercised in the future.
  • Total Capital Raised: With this partial exercise, the total number of units sold in the IPO has increased to 28,386,008 units, resulting in total gross proceeds of \$283,860,080.
  • Unit Structure: Each unit sold consists of one Class A ordinary share and one-sixth of one redeemable warrant. Each whole warrant allows the holder to purchase one Class A ordinary share at a price of \$11.50 per share.
  • Trading Information: Once the units begin separate trading, the Class A ordinary shares and warrants will trade on Nasdaq under the ticker symbols “ACAA” and “ACAAW”, respectively.
  • Book-Running Manager: Deutsche Bank Securities Inc. acted as the sole book-running manager for the offering.
  • Regulatory Compliance: The offering was made pursuant to a registration statement filed with and declared effective by the U.S. Securities and Exchange Commission (SEC) on February 18, 2026.

Shareholder Considerations & Price-Sensitive Information

  • Potential Impact on Share Value: The successful partial exercise of the over-allotment option demonstrates underwriter and market confidence in the company, which could be positively interpreted by investors and potentially support the share price.
  • Future Capital Raising Potential: The underwriter still has the option to purchase an additional 363,992 units. If exercised, this could further increase cash on hand and dilute existing shareholdings slightly, factors which investors should monitor closely.
  • Use of Proceeds: While the company has outlined intended uses for the IPO proceeds, the press release cautions that there is no assurance the net proceeds will be used as indicated, subject to conditions beyond the company’s control. Investors should review risk disclosures and company filings for further details.
  • Forward-Looking Statements: The release includes forward-looking statements regarding the use of funds and future performance, which are subject to various risks and uncertainties. Shareholders are encouraged to review the Risk Factors section of the registration statement and prospectus for more information.

Contact Information

For further inquiries, investors can contact:


Disclaimer

This article is for informational purposes only and does not constitute investment advice or an offer to buy or sell any securities. Investors should conduct their own due diligence and consult a financial advisor before making investment decisions. Forward-looking statements are subject to risks detailed in company filings with the SEC, available at www.sec.gov.




View Averin Capital Acquisition Corp. Historical chart here



Delcath Systems’ CHOPIN Phase 2 Trial Shows Improved Survival with Combined Hepatic Perfusion and Immunotherapy in Metastatic Uveal Melanoma (Published in The Lancet Oncology)

Delcath Systems Announces Landmark CHOPIN Trial Results in The Lancet Oncology Delcath Systems Announces Landmark CHOPIN Trial Results in The Lancet Oncology Key Points and Investor Highlights Full results of the CHOPIN Phase 2...

OFG Bancorp 2025 10-K/A Filing: Amendment Details, Company Information, and SEC XBRL Report

OFG Bancorp Files Amendment to Annual Report: Correction to Cover Page on Well-Known Seasoned Issuer Status Key Highlights: OFG Bancorp has filed Amendment No. 1 to its Annual Report on Form 10-K for the...

Canton Strategic Holdings CEO Mark Wendland Elected to Canton Foundation Board, Advancing Institutional Blockchain Adoption 1

Canton Strategic Holdings CEO Joins Canton Foundation Board: Key Implications for Investors Canton Strategic Holdings CEO Joins Canton Foundation Board: Key Implications for Investors Key Highlights Mark Wendland, Chairman and CEO of Canton Strategic...

   Ad